Charles River Laboratories International, Inc. balance sheet CRL

Annual Quarterly

As of Sep 26, 2026, Charles River Laboratories International, Inc. had total assets of $7.5 billion and total liabilities of $4.2 billion. Total assets were down 0.8% from a year earlier. Stockholders' equity was $3.2 billion. It held $200.4 million in cash and investments against $417.1 million of total debt, net debt of $216.7 million. The current ratio, current assets divided by current liabilities, was 1.41.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 26, 2026	FY 2025 Dec 27, 2025	FY 2024 Dec 28, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 25, 2021	FY 2020 Dec 26, 2020	FY 2019 Dec 28, 2019	FY 2018 Dec 29, 2018	FY 2017 Dec 30, 2017	FY 2016 Dec 31, 2016
Assets
Cash	200 -3.2%	214 +9.8%	195 -29.7%	277 +18.3%	234 -3.0%	241 +5.6%	228 -4.0%	238 +21.8%	195 +19.3%	164 +39.2%	118 -0.3%
Short-term investments	—	—	—	—	—	1 +3.8%	1 +8.8%	1 +6.3%	1 -96.9%	28 +655.5%	4
Cash and investments	200 -3.2%	214 +9.8%	195 -29.7%	277 +18.3%	234 -3.5%	242 +5.6%	229 -4.0%	239 +21.7%	196 +2.1%	192 +58.4%	121 -19.4%
Receivables	735 +0.1%	709 -1.7%	721 -7.6%	780 +3.7%	752 +17.0%	643 +4.1%	618 +20.2%	514 +8.8%	472 +9.8%	430 +18.1%	364 +34.8%
Inventory	320 +5.6%	299 +7.4%	279 -26.7%	380 +48.6%	256 +28.5%	199 +7.2%	186 +15.6%	161 +25.6%	128 +11.3%	115 +20.0%	96 +2.2%
Total current assets	1,535 +0.2%	1,447 +3.1%	1,403 -12.8%	1,609 +11.8%	1,439 +12.9%	1,274 +6.1%	1,201 +17.6%	1,021 +13.8%	898 +8.6%	827 +25.9%	657 +17.5%
Property and equipment, net	1,497 -5.9%	1,655 +3.2%	1,604 -2.2%	1,640 +11.9%	1,466 +13.5%	1,291 +14.8%	1,124 +7.7%	1,044 +11.9%	933 +19.3%	782 +3.5%	756 +11.5%
Goodwill	3,084 +5.5%	2,764 -2.9%	2,847 -8.0%	3,095 +8.6%	2,850 +5.1%	2,712 +49.9%	1,809 +17.4%	1,541 +23.5%	1,247 +54.9%	805 +2.2%	788 +79.5%
Total assets	7,452 -0.8%	7,135 -5.2%	7,528 -8.1%	8,195 +7.8%	7,603 +8.2%	7,024 +27.9%	5,491 +17.0%	4,693 +21.7%	3,856 +31.6%	2,930 +8.0%	2,712 +31.1%
Liabilities and equity
Accounts payable	145 -14.8%	149 +6.0%	140 -16.9%	169 -18.0%	206 +3.9%	198 +61.8%	122 +9.8%	111 +68.3%	66 -14.9%	78 +13.7%	68 +86.7%
Total current liabilities	1,089 -2.9%	1,120 +12.7%	994 -5.8%	1,055 -3.3%	1,092 +5.7%	1,033 +23.0%	840 +18.2%	710 +27.2%	558 +20.4%	464 +7.9%	430 +37.8%
Total liabilities	4,176 +2.8%	3,924 -2.4%	4,020 -11.4%	4,536 -0.9%	4,579 +3.3%	4,432 +32.4%	3,347 +10.6%	3,026 +20.2%	2,518 +34.9%	1,866 +0.4%	1,858 +42.6%
Stockholders' equity	3,227 -5.2%	3,165 -8.6%	3,462 -3.8%	3,597 +20.9%	2,976 +17.4%	2,535 +19.9%	2,115 +29.4%	1,635 +24.1%	1,317 +26.1%	1,045 +24.9%	837 +14.1%
Debt
Debt due within a year	2 +3781.5%	0 +7.1%	0 -95.1%	3 +135.5%	1 +1233.7%	0 -99.8%	47 +32.8%	36 +25.9%	28 -1.1%	29 +16.2%	25 +61.7%
Long-term debt	—	—	—	—	—	—	—	—	1,627 +49.0%	1,092 -8.1%	1,188 +44.7%
Lease liabilities	415 -11.9%	520 -8.3%	566 +12.7%	503 +7.7%	467 +49.0%	313 +49.8%	209 +25.2%	167	—	—	—
Total debt	417 -11.5%	520 -8.3%	567 +12.0%	506 +8.0%	468 +49.3%	314 +22.2%	257 +26.6%	203 -87.8%	1,655 +47.7%	1,121 -7.6%	1,213 +45.0%
Net cash	-217 +18.0%	-306 +17.7%	-372 -62.4%	-229 +2.2%	-234 -228.7%	-71 -163.4%	-27 -174.6%	36 +102.5%	-1,459 -57.1%	-928 +14.9%	-1,091 -59.2%
Ratios
Current ratio	1.41x	1.29x	1.41x	1.52x	1.32x	1.23x	1.43x	1.44x	1.61x	1.78x	1.53x
Debt to equity	0.13x	0.16x	0.16x	0.14x	0.16x	0.12x	0.12x	0.12x	1.26x	1.07x	1.45x
Debt to EBITDA	0.94x	1.21x	0.96x	0.54x	0.49x	0.37x	0.38x	0.37x	3.36x	2.67x	3.33x
Return on equity	1.25%	-4.56%	0.64%	13.20%	16.34%	15.42%	17.23%	15.42%	17.18%	11.80%	18.50%
Return on assets	0.54%	-2.02%	0.29%	5.79%	6.40%	5.57%	6.63%	5.37%	5.87%	4.21%	5.71%
Book value per share	67.40	64.30	67.69	70.06	58.42	50.21	42.49	33.40	27.33	22.05	17.67

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Services-Commercial Physical & Biological Research (SIC 8731)
Listed as: CRL (NYSE)
Fiscal year ends: December 27
Headquarters: Wilmington, MA
SEC filer status: Large accelerated filer
SEC CIK: 1100682
Former names: CHARLES RIVER LABORATORIES INTERNATIONAL INC (until May 30, 2019); CHARLES RIVER LABORATORIES HOLDINGS INC (until Jan 28, 2000)

Other Services-Commercial Physical & Biological Research companies

All 17 Services-Commercial Physical & Biological Research companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.